Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease
Clinical Parkinsonism & Related Disorders · 2026 · 15 · 100466
DOI: 10.1016/j.prdoa.2026.100466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2026. Verfasst von Matteo Alessandro De Rosa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Continuous subcutaneous levodopa infusion is an established option for advanced Parkinson's disease (PD). Subcutaneous levodopa/carbidopa infusion (ND0612) and foslevodopa/foscarbidopa (ABBV-951) are available infusion systems; however, no clinical guidance exists regarding conversion between these treatments.
Methods
We report two patients with advanced PD receiving ND0612 in combination with oral levodopa who underwent complete transition to ABBV-951. Initial foslevodopa/foscarbidopa dosing was estimated according to levodopa equivalent daily dose and subsequently titrated under close neurological supervision. Motor fluctuations, non-motor symptoms, quality of life, and infusion-site tolerability were evaluated at baseline and at 3-month follow-up using standardized clinical assessments.
Results
Both transitions were completed within one day without acute adverse events. At three months, both patients showed a marked reduction in daily off time, improvement in dyskinesias and freezing of gait, and stabilization of sleep and behavioral symptoms. ABBV-951 demonstrated improved local tolerability, with no infusion-site complications observed during follow-up.
Conclusions
Conversion from ND0612 to ABBV-951 appears feasible, and safe in advanced PD. These preliminary observations may provide practical insight in the absence of published data addressing this specific therapeutic transition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
- Neurology Institute, SS. Annunziata University Hospital, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
- Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
- Institute for Advanced Biomedical Technologies (ITAB), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Zitieren
APA
De Rosa, M. A., Calisi, D., Russo, M., Thomas, A., & Sensi, S. L. (2026). Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease. Clinical Parkinsonism & Related Disorders, 15, 100466. https://doi.org/10.1016/j.prdoa.2026.100466
Vancouver
De Rosa MA, Calisi D, Russo M, Thomas A, Sensi SL. Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease. Clinical Parkinsonism & Related Disorders. 2026;15:100466. doi:10.1016/j.prdoa.2026.100466
BibTeX
@article{DeRosa2026,
author = {De Rosa, Matteo Alessandro and Calisi, Dario and Russo, Mirella and Thomas, Astrid and Sensi, Stefano Luca},
title = {Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease},
journal = {Clinical Parkinsonism & Related Disorders},
year = {2026},
volume = {15},
pages = {100466},
doi = {10.1016/j.prdoa.2026.100466}
}
EUVIMED